This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): GZ402665, Recombinant Acid Sphingomyelinase, rhASM, SAR402665
Olipudase alfa is a recombinant human acid sphingomyelinase. Acid sphingomyelinases catalyze the breakdown of sphingomyelin to ceramide and phosphorylcholine. Lack of the enzyme causes Niemann–Pick disease (NPD) types A (a neuronopathic form) and B (a nonneuronopathic form).
Since olipudase does not cross the blood brain barrier, it is being developed for Niemann-Pick type B disease, where non-neurologic symptoms predominate.
Olipudase Alfa News
Additional information available to subscribers only: